Susquehanna International Group’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.1M | Buy |
+314,000
| New | +$5.56M | ﹤0.01% | 4184 |
|
|
2025
Q4 | – | Sell |
-45,300
| Closed | -$661K | – | 13601 |
|
|
2025
Q3 | $661K | Buy |
45,300
+33,700
| +291% | +$426K | ﹤0.01% | 8343 |
|
|
2025
Q2 | $128K | Buy |
+11,600
| New | +$113K | ﹤0.01% | 11622 |
|
|
2024
Q4 | – | Sell |
-11,600
| Closed | -$93.5K | – | 13196 |
|
|
2024
Q3 | $93.5K | Buy |
+11,600
| New | +$100K | ﹤0.01% | 11090 |
|
|
2023
Q3 | – | Sell |
-11,700
| Closed | -$121K | – | 12957 |
|
|
2023
Q2 | $121K | Sell |
11,700
-14,700
| -56% | -$162K | ﹤0.01% | 10786 |
|
|
2023
Q1 | $286K | Sell |
26,400
-4,000
| -13% | -$42.3K | ﹤0.01% | 9827 |
|
|
2022
Q4 | $341K | Sell |
30,400
-131,500
| -81% | -$1.38M | ﹤0.01% | 8788 |
|
|
2022
Q3 | $1.64M | Buy |
161,900
+63,500
| +65% | +$595K | ﹤0.01% | 5368 |
|
|
2022
Q2 | $892K | Sell |
98,400
-22,000
| -18% | -$203K | ﹤0.01% | 6801 |
|
|
2022
Q1 | $1.15M | Buy |
120,400
+99,600
| +479% | +$976K | ﹤0.01% | 6773 |
|
|
2021
Q4 | $230K | Sell |
20,800
-130,700
| -86% | -$1.14M | ﹤0.01% | 11137 |
|
|
2021
Q3 | $1.12M | Buy |
151,500
+140,900
| +1,329% | +$1.58M | ﹤0.01% | 7260 |
|
|
2021
Q2 | $154K | Sell |
10,600
-37,000
| -78% | -$695K | ﹤0.01% | 11836 |
|
|
2021
Q1 | $972K | Buy |
+47,600
| New | +$905K | ﹤0.01% | 7818 |
|
|
2020
Q4 | – | Sell |
-40,200
| Closed | -$594K | – | 11720 |
|
|
2020
Q3 | $594K | Buy |
40,200
+12,800
| +47% | +$240K | ﹤0.01% | 7316 |
|
|
2020
Q2 | $575K | Buy |
+27,400
| New | +$704K | ﹤0.01% | 7086 |
|
|
2019
Q3 | – | Sell |
-30,500
| Closed | -$498K | – | 10835 |
|
|
2019
Q2 | $498K | Buy |
30,500
+8,100
| +36% | +$164K | ﹤0.01% | 7268 |
|
|
2019
Q1 | $508K | Buy |
+22,400
| New | +$568K | ﹤0.01% | 6239 |
|
|
2018
Q1 | – | Sell |
-20,100
| Closed | -$561K | – | 10162 |
|
|
2017
Q4 | $561K | Sell |
20,100
-1,200
| -6% | -$35.5K | ﹤0.01% | 6418 |
|
|
2017
Q3 | $729K | Buy |
+21,300
| New | +$697K | ﹤0.01% | 5854 |
|
|
2017
Q2 | – | Sell |
-8,500
| Closed | -$313K | – | 9825 |
|
|
2017
Q1 | $313K | Sell |
8,500
-2,100
| -20% | -$67.1K | ﹤0.01% | 7278 |
|
|
2016
Q4 | $338K | Buy |
10,600
+900
| +9% | +$27.9K | ﹤0.01% | 7761 |
|
|
2016
Q3 | $352K | Buy |
+9,700
| New | +$270K | ﹤0.01% | 6665 |
|
|
2015
Q3 | – | Sell |
-12,100
| Closed | -$158K | – | 10182 |
|
|
2015
Q2 | $158K | Buy |
+12,100
| New | +$188K | ﹤0.01% | 9465 |
|
Other funds holding TBPH
MAP
WAM
NM
ICM
VCM
Susquehanna International Group's TBPH Position: Q1 2026 in Review
Susquehanna International Group increased its Theravance Biopharma (TBPH) stake by 1,460% in Q1 2026, buying an estimated $5.66M and bringing the position to 341,579 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #4058.
Susquehanna International Group first reported a position in TBPH in Q2 2014 and has held it in 32 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.
- Susquehanna International Group held 341,579 shares of Theravance Biopharma worth $5.54M as of Q1 2026.
- Susquehanna International Group bought 319,683 Theravance Biopharma shares in Q1 2026, an estimated $5.66M.
- Theravance Biopharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4058 holding.
- Susquehanna International Group first reported a position in Theravance Biopharma in Q2 2014 and has held it in 32 quarters since.
- 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.